Switch from entecavir to tenofovir for chronic hepatitis B
Treatments studied
Part of Infections clinical trials.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old
- Your blood test shows active hepatitis B (HBsAg is detectable)
- You have chronic hepatitis B and are currently taking entecavir (ETV)
- You feel your entecavir treatment is not effective enough or is inconvenient
- You have no known medical reason you can’t safely take tenofovir (TAF)
- You expect to be able to stay on hepatitis B antiviral treatment for at least 1 more year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This trial tests whether switching to a newer antiviral medicine called tenofovir alafenamide (TAF, a pill for hepatitis B) is safe and works well for people who have had a liver transplant. The goal is to keep the liver healthy and reduce side effects compared to current treatment.
This trial tests whether switching from the regular entecavir pill to a new orally dissolving version works just as well and is safe for patients who have had a liver transplant due to hepatitis B. If you've been stable on entecavir, this could be a convenient alternative.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
This study looks at whether hepatitis B virus becomes resistant to a drug called entecavir in people in Turkey. It may help doctors understand why some people's treatment stops working.
Hear when a new Patient Satisfaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.